Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 3, 2013, Pages

  Shiu, Jennifer ^a   Wang, Erica ^b   Tejani, Aaron M ^c   Wasdell, Michael ^d  

^a ALBERTA HEALTH SERVICES   (Canada)

^b KELOWNA GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Bridgepoint Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; LINEZOLID; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

AGE; ALL CAUSE MORTALITY; BACTERIAL INFECTION; BACTERIUM CULTURE; COMORBIDITY; CONTINUOUS INFUSION; DEATH; DERMATITIS; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; ETHNICITY; FEVER; FOLLOW UP; GENDER; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; LIFE THREAT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SEPSIS; SIDE EFFECT; SKIN DEFECT; SKIN REDNESS; SUPERINFECTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VITAL SIGN; ACUTE DISEASE; ADULT; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; METABOLISM; METHODOLOGY; MORTALITY;

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

MLCS; MLOWN;

EID: 84880051025     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008481.pub2     Document Type: Review

References (99)

1. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. International Journal of Antimicrobial Agents 2008;31(2):122-9.
2. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology 2000;49(5):445-52.
3. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine 1979;67(4):608-16.
4. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. International Journal of Antimicrobial Agents 2005;25(1):62-7.
5. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Critical Care 2012;16:R113 (Epub ahead of print).
6. Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, Lamiable D, Hoizey G. Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia (French). Pathologie Biologie 2005;53:546-50.
7. De Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy 2008;61(2):382-8.
8. Feld R, Valdivieso M, Bodey GP, Rodriguez V. A comparative trial of sisomicin therapy by intermittent versus continuous infusion. The American Journal of the Medical Sciences 1977;274(2):179-88.
9. Feld R, Rachlis A, Tuffnell PG, Duncan I, Moran L, Pinfold P, DeBoer G. Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole. Archives of Internal Medicine 1984;144(5):1005-10.
10. Georges B, Conil JM, Cougot P, Decun JF, Archambaud M, Seguin T, Chabanon G, Virenque C, Houin G, Saivin S. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. International Journal of Clinical Pharmacology and Therapeutics 2005;43(8):360-9.
11. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. The American Journal of Surgery 2000;179(6):436-40.
12. Lagast H, Meunier-Carpentier F, Klastersky J. Treatment of gram-negative bacillary septicemia with cefoperazone. European Journal of Clinical Microbiology 1983;2(6):554-8.
13. Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrobial Agents and Chemotherapy 2006;50(11):3556-61.
14. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy 1999;43(2):309-11.
15. Lubasch A, Luck S, Hartmut L, Mauch H, Lorenz J, Bolcskei P, Welte T. Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. Journal of Antimicrobial Chemotherapy 2003;51:659-64.
16. Nicolau DP, McNabb J, Lacy MK, Li J, Quintiliani R, Nightingale CH. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clinical Drug Investigation 1999;18(2):133-9.
17. Nicolau DP, Lacy MK, McNabb J, Quintiliani R, Nightingale CH. Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infectious Diseases in Clinical Practice 1999;8(1):45-9.
18. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. International Journal of Antimicrobial Agents 2001;17(6):497-504.
19. Okimoto N, Ishiga M, Nanba F, Kibayashi T, Kishimoto M, Kurihara T, Honda Y, Asaoka N, Tamada S. Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly (Japanese). Nihon Kokyuki Gakkai Zasshi 2009;47(7):553-7.
20. Pedeboscq S, Dubau B, Frappier S, Hernandez V, Veyssieres D, Winnock S, Pometan JP. Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin (French). Pathologie Biologie (Paris) 2001;49(7):540-7.
21. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. International Journal of Antimicrobial Agents 2006;28(2):122-7.
22. Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, Richards B, Lipman J. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy 2007;59(2):285-91.
23. Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy 2009;64(1):142-50.
24. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration?. Critical Care Medicine 2009;37(3):926-33.
25. Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents 2010;35:156-63.
26. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrobial Agents and Chemotherapy 2007;51(9):3304-10.
27. van Zanten ARH, Oudijk M, Nohlmans-Paulssen MKE, van der Meer YG, Girbes ARJ, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. British Journal of Clinical Pharmacology 2007;63(1):100-9.
28. Wright JP, Potgieter PD, Forder AA, Botha P, Brinkworth G, Elisha G, Ferguson AD. Gentamicin and penicillin in the treatment of severe respiratory infections. South African Medical Journal 1979;55(6):197-200.
29. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D, and the study group. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrobial Agents and Chemotherapy 2001;45(9):2460-7.
30. Adembri C, Ristori R, Chelazzi C, Arrigucci S, Cassetta MI, De Gaudio AR, Novelli A. Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. Journal of Thoracic and Cardiovascular Surgery 2010;140:471-5.
31. Ambrose PG, Quindliani R, Nightingale CH, Nicolau DP. Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. Infectious Diseases in Clinical Practice 1998;7(9):463-70.
32. Benko A, Cappelletty D, Kruse J, Rybak M. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrobial Agents and Chemotherapy 1996;40(3):691-95.
33. Bosso J, Bonapace C, Flume P, White R. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 1999;19(5):620-26.
34. Buijk SLCE, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. Journal of Antimicrobial Chemotherapy 2002;49(1):121-8.
35. Burgess D, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clinical Therapeutics 2002;24(7):1090-1104.
36. DeRyke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection. American Journal of Health System Pharmacy 2006;63(8):750-5.
37. Georges B, Archambaud M, Saivin S, Decun J, Cougot P, Mazerolles M, Andrieu P, Suc C, Houin G, Chabanon G, Virenque C. Continuous versus intermittent cefepime infusion in critical care. Preliminary results (French). Pathologie Biologie 1999;47(5):483-85.
38. Grant E, Kuti J, Nicolau D, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22(4):471-83.
39. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Muller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery. Anesthesiology 2009;111:356-65.
40. James J, Palmer S, Levine D, Rybak M. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrobial Agents and Chemotherapy 1996;40(3):696-700.
41. Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with gram-negative bacilli bacteraemia. Journal of Pharmacy and Pharmacology 2002;54:1693-96.
42. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrobial Agents and Chemotherapy 2005;49(4):1337-39.
43. Jaruratanasirikul S, Sudsai T. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5h infusion. Journal of Anitimicrobial Chemotherapy 2009;63:560-63.
44. Jaruratanasirikul S, Julamanee J, Sudsai T, Saengsuwan P, Jullangkoon M, Ingviya N, Jarumanokul R. Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus. Journal of the Medical Association of Thailand 2010;93(2):172-6.
45. Kickpatrick C, Howard G, Vella-Brincat J. Comment: serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients. The Annals of Pharmacotherapy 2001;53:1295-96.
46. Klepser M, Patel K, Nicolau D, Quintiliani R, Nightingale C. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant staphylococcus aureus and enterococcus faecalis. Pharmacotherapy 1998;18(5):1069-74.
47. Kojika M, Sato N, Hakozaki M, Suzuki Y, Takahasi G, Endo S, Suzuki K, Wakabayasi G. A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of administration time. The Japanese Journal of Antibiotics 2005;58(5):452-7.
48. Langgartner J, Lehn N, Gluck T, Herzig H, Kees F. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemotherapy 2007;53:370-77.
49. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. Journal of Antimicrobial Chemotherapy 2005;56(2):388-95.
50. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Annals of Pharmacotherapy 2006;40:219-23.
51. Martin C, Cotin A, Giraud A, Beccani-Argeme M, Alliot P, Mallet MN, Argeme M. Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery. Antimicrobial Agents and Chemotherapy 1998;42(5):1093-97.
52. McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001;21(5):549-55.
53. Nicasio A, Quintiliani R, DeRyke C, Kuti J, Nicolau D. Treatment of serratia marcescens meningitis with prolonged infusion of meropenem. The Annals of Pharmacotherapy 2007;41:1077-81.
54. Pass SE, Miyagawa CI, Healy DP, Ivey TD. Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients. Annals of Pharmacotherapy 2001;35:409-13.
55. Schuster KM, Wilson D, Schulman CI, Pizano LR, Ward CG, Namias N. Continuous infusion oxacillin for the treatment of burn wound cellulitis. Surgical Infections 2009;10(1):41-5.
56. Seguin P, Verdier M, Chanavaz C, Engrand C, Laviolle B, Donnio P, Malledant Y. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis. Journal of Antimicrobial Chemotherapy 2009;63:564-67.
57. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein U, Locker G, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H. Continuous infusion versus intermittent administration of meropenem in critically ill patients. Journal of Antimicrobial Chemotherapy 1999;43:523-27.
58. Vinks A, Hollander J, Overbeek S, Jelliffe R, Mouton J. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent of continuous infusion in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2003;47(2):541-47.
59. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, Bernard L. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. Journal of Clinical Pharmacy and Therapeutics 2004;29:351-57.
60. Waltrip T, Lewis R, Young V, Farmer M, Clayton S, Myers S, Gray L, Galandiuk S. A pilot study to determine the feasibility of continuous cefazolin infusion. Surgical Infections 2002;3(1):5-9.
61. Cousson J, Floch T, Hoizey G, Nicolai F, Guillard T, Vernet-Garnier V. Comparison of pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in epithelial lining fluid concentrations of patients with severe nosocomial pneumonia. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (poster) 2010.
62. Johnson P. A Randomised controlled crossover pilot study of meropenem standard 30 minute infusion versus prolonged 3 hour infusion in intensive care patients. Available at http://www.clinicaltrials.gov, last updated July 2012. Accessed November 14, 2012.
63. Cortes D. Pharmacokinetic study of extended infusion meropenem in adult cystic fibrosis patients with exacerbation of pulmonary infection. Available at http://www.clinicaltrials.gov, last updated June 2012. Accessed November 14, 2012.
64. Decruyenaere J. Assessment of the optimal dosing of piperacillin-tazobactam in intensive care unit patients: extended versus continuous infusion. Available at http://www.clinicaltrials.gov, last updated July 2012. Accessed November 14, 2012.
65. Jaruratanasirikul S. The pharmacodynamics of imipenem in critically ill patients with ventilator-associated pneumonia following administration by 4h or 0.5h infusion. Available at http://www.clinicaltrials.gov, last updated December 2011. Accessed November 14, 2012.
66. Gil-Navarro MV. Efficacy and safety of piperacillin-tazobactam continuous infusion vs intermittent infusion for complicated or nosocomial Pseudomonas aeruginosa infection or suspected infection. Available at http://www.clinicaltrials.gov, last updated April 2012. Accessed November 14, 2012.
67. Peleg A. Continuous infusion anti-pseudomonal beta-lactams for the treatment of acute, infective pulmonary exacerbations in cystic fibrosis: a prospective randomised controlled trial. Available at http://www.clinicaltrials.gov, last updated August 2012. Accessed November 14, 2012.
68. Fisher D. Reducing nephrotoxicity of vancomycin: a prospective, randomised study of continuous versus intermittent infusion of vancomycin. Available at http://www.clinicaltrials.gov, last updated November 2012. Accessed November 14, 2012.
69. Ariano R, Zelenitsky S, McCormack J. Should IV antibiotics be administered by prolonged infusion?. Canadian Journal of Hospital Pharmacy 2010;63(3):246-9.
70. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Flack-Ytter Y, Meerpohl J, Norris S, Guyall GH. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64:401-06.
71. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 1998;26(1):1-10.
72. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nature Reviews Microbiology 2004;2(4):289-300.
73. Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. American Journal of Health System Pharmacy 2003;60(22):2321-7.
74. Ghafourian S, Sekawi Z, Sadeghifard N, Mohebi R, Neela VK, Maleki A, Hematian A, Rahbar M, Raftari M, Ranjbar R. The prevalence of ESBLs producing Klebsiella pneumoniae isolates in some major hospitals, Iran. The Open Microbiology Journal 2011;5:91-5.
75. Version 3.2 for Windows. Brozek J, Oxman A, Schunemann H. GRADEpro (GRADEprofiler). The Cochrane Collaboration, 2008.
76. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, deBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383-94.
77. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
78. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
79. Hitt CM, Nighingale CH, Quintilliani R, Nicolau DP. Cost comparison of single daily IV doses of ceftriaxone versus continuous infusion of cefotaxime. American Journal of Health System Pharmacy 1997;54(14):1614-8.
80. Kasiakou SK, Lawrence KR, Choulis N, Falagas ME. Continuous versus intermittent intravenous administration of antibacterials with time- dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 2005;65(17):2499-511.
81. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infectious Diseases 2005;5(9):581-9.
82. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Medicine 2001;27(2):363-70.
83. Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on B-lactam antibiotics. Pharmacotherapy 2006;26(9):1320-32.
84. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for pseudomonas aeruginosa Infection: clinical implications of an extended-infusion dosing strategy. Clinical Infectious Diseases 2007;44(3):357-63.
85. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. International Journal of Antimicrobial Agents 2008;31(4):345-51.
86. Meyer E, Ziegler R, Mattner F, Schwab F, Gastmeier P, Martin M. Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum B-lactamase-producing Enterobacteriaceae. Infection 2011;39(6):501-6.
87. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 1987;155(1):93-9.
88. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, Larson EL. Costs of healthcare- and community-associated infections with antimicrobial-resistance versus susceptible organisms. Clinical Infectious Diseases 2012;Jun 14:(epub ahead of print).
89. Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent infections. Antimicrobial Agents and Chemotherapy 1996;40(1):61-4.
90. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
91. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clinical Pharmacokinetics 2006;45(8):755-73.
92. Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Current Opinion in Critical Care 2008;14(4):390-6.
93. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of B-lactam antibiotics. Critical Care Medicine 2009;37(6):2071-8.
94. Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, Leblebicioglu H, Fisher D, Alvarez-Moreno C, Khader IA, Martinez M, Cuellar LE, Navoa-Ng JA, Abouqal R, Garcell HG, Mitrev Z, Garcia MCP, Hamdi A, Duenas L, Cancel E, Gurskis V, Rasslan O, Ahmed A, Kanj SS, Ugalde OC, Mapp T, Raka L, Meng CY, Thu LA, Ghazal S, Gikas A, Narvaez LP, Mejia N, Hadjieva N, Elanbya MOG, Siritt MEG, Jayatilleke K, INICC members. International nosocomial infection control consortium (INICC) report, data summary of 36 countries, for 2004-2009. American Journal of Infection Control 2012;40(5):396-407.
95. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Peri TM, Standiford HC, Srinivasan A. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerging Infectious Diseases 2007;13(1):97-103.
96. Tamma PD, Putcha N, Suh YD, Van Arendonk KJ, Rinke ML. Does prolonged B-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infectious Diseases 2011;11:181.
97. van Zanten AR. The jury is still out on continuous infusion of B-lactam antibiotics in intensive care patients. Critical Care Medicine 2009;37(6):2137-8.
98. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq M, Tulkens P. Comparative stability studies of antipseudomonal B-Lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrobial Agents and Chemotherapy 2002;46(8):2327-32.
99. Yu IS, Tejani AM, Wasdell M. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD008481]